Letter

Folate and risk of cardiovascular disease

BMJ 2003; 326 doi: 10.1136/bmj.326.7397.1035/a (Published 10 May 2003)
Cite this as: BMJ 2003;326:1035.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Study results were misinterpreted

  1. David S Wald, specialist registrar in cardiology (davidwald@hotmail.com),
  2. Malcolm Law, professor,
  3. Joan Morris, senior lecturer,
  4. Nicholas J Wald, professor
  1. Southampton General Hospital, Southampton SO16 6YD
  2. Department of Environmental and Preventive Medicine, London EC1M 6BQ
  3. School of Medicine and Pharmacology, University of Western Australia, Nedlands, WA 6009, Australia

    EDITOR—Hung et al conclude that their cohort study on serum folate and coronary heart disease provides evidence against the view that folic acid prevents coronary heart disease.1 We disagree and believe they have misinterpreted their results.

    A meta-analysis of studies on homocysteine and cardiovascular disease, supported by others,2–4 together with randomised trial evidence on folic acid dose and serum homocysteine reduction, shows that the maximal homocysteine lowering effect of folic acid occurs at a dose of about 0.8 mg/day (which increases serum folate by 20 µg/l).5 This homocysteine reduction lowers the risk of coronary heart disease by about 16%. The difference in average serum folate between the highest and the lowest folate group in the cohort study of Hung et al was about 7 µg/l, since the …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular